Market Closed -
Bombay S.E.
11:14:08 31/07/2023 BST
|
5-day change
|
1st Jan Change
|
4.9
INR
|
-3.92%
|
|
-.--%
|
-.--%
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
5,872
|
1,919
|
601.1
|
1,335
|
1,202
|
547.2
|
Enterprise Value (EV)
1 |
13,121
|
10,521
|
9,523
|
4,527
|
4,719
|
4,320
|
P/E ratio
|
7.62
x
|
3.49
x
|
-0.55
x
|
-1.86
x
|
-1.78
x
|
-0.17
x
|
Yield
|
0.56%
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
0.49
x
|
0.14
x
|
0.06
x
|
0.15
x
|
0.5
x
|
0.29
x
|
EV / Revenue
|
1.1
x
|
0.79
x
|
0.89
x
|
0.52
x
|
1.98
x
|
2.3
x
|
EV / EBITDA
|
6.32
x
|
5.56
x
|
48.7
x
|
9.31
x
|
-69.7
x
|
-2.32
x
|
EV / FCF
|
-8.33
x
|
7.92
x
|
24.7
x
|
2.29
x
|
-35.1
x
|
6.39
x
|
FCF Yield
|
-12%
|
12.6%
|
4.04%
|
43.6%
|
-2.85%
|
15.7%
|
Price to Book
|
0.65
x
|
0.31
x
|
0.12
x
|
0.31
x
|
0.33
x
|
1.39
x
|
Nbr of stocks (in thousands)
|
82,524
|
82,524
|
82,914
|
82,914
|
82,914
|
82,914
|
Reference price
2 |
71.15
|
23.25
|
7.250
|
16.10
|
14.50
|
6.600
|
Announcement Date
|
12/09/18
|
07/09/19
|
08/12/20
|
13/01/23
|
03/03/23
|
20/10/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
11,953
|
13,381
|
10,671
|
8,713
|
2,386
|
1,881
|
EBITDA
1 |
2,075
|
1,891
|
195.4
|
486.4
|
-67.72
|
-1,859
|
EBIT
1 |
1,510
|
1,223
|
-474
|
-68.51
|
-250.5
|
-2,050
|
Operating Margin
|
12.64%
|
9.14%
|
-4.44%
|
-0.79%
|
-10.5%
|
-109.03%
|
Earnings before Tax (EBT)
1 |
857.1
|
660.4
|
-1,095
|
-698.6
|
-648.3
|
-3,306
|
Net income
1 |
779.4
|
573.6
|
-1,091
|
-718.9
|
-676.5
|
-3,285
|
Net margin
|
6.52%
|
4.29%
|
-10.23%
|
-8.25%
|
-28.36%
|
-174.69%
|
EPS
2 |
9.332
|
6.670
|
-13.16
|
-8.670
|
-8.159
|
-39.62
|
Free Cash Flow
1 |
-1,575
|
1,329
|
385.1
|
1,973
|
-134.3
|
676.3
|
FCF margin
|
-13.18%
|
9.93%
|
3.61%
|
22.65%
|
-5.63%
|
35.96%
|
FCF Conversion (EBITDA)
|
-
|
70.29%
|
197.12%
|
405.69%
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
231.7%
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
0.4000
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/09/18
|
07/09/19
|
08/12/20
|
13/01/23
|
03/03/23
|
20/10/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
7,250
|
8,602
|
8,922
|
3,192
|
3,517
|
3,773
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
3.494
x
|
4.549
x
|
45.67
x
|
6.562
x
|
-51.93
x
|
-2.029
x
|
Free Cash Flow
1 |
-1,575
|
1,329
|
385
|
1,973
|
-134
|
676
|
ROE (net income / shareholders' equity)
|
7.71%
|
5.26%
|
-12.3%
|
-11.4%
|
-17%
|
-163%
|
ROA (Net income/ Total Assets)
|
4.24%
|
3.24%
|
-1.31%
|
-0.24%
|
-1.23%
|
-11.4%
|
Assets
1 |
18,394
|
17,723
|
83,587
|
293,772
|
55,202
|
28,896
|
Book Value Per Share
2 |
109.0
|
75.00
|
61.40
|
52.10
|
43.90
|
4.750
|
Cash Flow per Share
2 |
12.00
|
11.50
|
6.090
|
0.7800
|
0.8700
|
0.4500
|
Capex
1 |
1,635
|
891
|
1,128
|
-
|
164
|
49.7
|
Capex / Sales
|
13.68%
|
6.66%
|
10.57%
|
-
|
6.88%
|
2.64%
|
Announcement Date
|
12/09/18
|
07/09/19
|
08/12/20
|
13/01/23
|
03/03/23
|
20/10/23
|
|
1st Jan change
|
Capi.
|
---|
| +54.07% | 816B | | +38.59% | 634B | | -7.05% | 351B | | +15.44% | 323B | | +5.72% | 293B | | +13.40% | 238B | | +0.61% | 222B | | +13.24% | 218B | | +7.42% | 167B |
Other Pharmaceuticals
|